Consistently, targeting VEGFR2 with either humanized monoclonal antibodies, such as bevacizumab and VEGF-Trap, or tyrosine kinase inhibitors (TKIs), such as sorafenib, sunitinib and pazopanib, halted neovessel formation and caused tumor shrinkage in immunodeficient mouse models of most malignancies [7, 8], including BC. Here, KDR is linked to breast cancer.